Byk moves Argentine operations to Brazil

19 July 2001

German pharmaceutical firm Byk Gulden, part of the Altana group, hasannounced plans to move its production activities in South America to Brazil from Argentina. The company is opening a new factory in the Sao Paulo area in November which will have the capacity to produce 60 million units per year. Byk is investing $56 million into the facility, and the first shipments to Argentina will begin a few months later.

Byk is transferring production in a bid to reduce costs and, being based in Brazil, will enable the firm to scale up operations in the region. However, it has not ruled out contract production of raw materials for other firms in Argentina. The company is hoping to balance a $10 million trade deficit in Brazil with sales to other Mercosur countries and grow its revenues in that country, which presently total $125 million per year.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight